Harrisvaccines Revenue and Competitors

Ames, IA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Harrisvaccines's estimated annual revenue is currently $2.5M per year.(i)
  • Harrisvaccines's estimated revenue per employee is $155,000

Employee Data

  • Harrisvaccines has 16 Employees.(i)
  • Harrisvaccines grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6-14%N/AN/A
#2
$16.1M1049%N/AN/A
#3
$0.8M10-44%$2.1MN/A
#4
$504.4M20341%$31.2MN/A
#5
$8.1M526%N/AN/A
#6
$2M130%N/AN/A
#7
$0.3M2-85%N/AN/A
#8
$0.2M10%N/AN/A
#9
$1.8M2344%N/AN/A
#10
$1.4M9-10%N/AN/A
Add Company

What Is Harrisvaccines?

Harrisvaccines is now part of Merck Animal Health. Please visit the Merck Animal Health LinkedIn page for more information! https://lnkd.in/b4pAgNB Harrisvaccines is revolutionizing the worlds' animal vaccine industry by providing herd-specific vaccines more quickly, safely and flexibly than any other brand. With its RNA Particle (RP) technology, the company is working to improve disease management and animal health. The RP technology Harrisvaccines deploys does not need the virus. Instead, it need only the data to determine the sub-type or strain of a specific virus. SirraVax takes the gene sequence from a diagnostic lab report to make every herd-specific vaccine rapidly, safely and economically. Porcine Epidemic Diarrhea vaccine, RNA - This product is Conditionally approved for safe, potent and reasonable expectation of efficacy against Porcine Epidemic Diarrhea virus (PEDv). Swine Influenza Vaccine, RNA - This products is licensed to be used as an aid in the prevention of disease caused by Swine Influenza, H3N2. United States Veterinary Biologics Establishment License Number 592.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$2.5M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.6M17-23%N/A
#2
$1.6M18-5%N/A
#3
$1.6M19-24%N/A
#4
$2.1M1912%N/A
#5
$4.5M205%N/A